Loading company…
Pragma Bio uses an AI-enabled platform to discover small molecules targeting the gut-immune axis.
Pragma Bio discovers small molecules from gut microbes for gastrointestinal and immune-related applications, using its AI-enabled PIKASO platform. Founded in 2018 and based in South San Francisco, US, the company raised USD 14.52 mn in Series A funding led by The Venture Collective. Kareem Barghouti is CEO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in